News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
689,466 Results
Type
Article (39207)
Company Profile (282)
Press Release (649977)
Section
Business (203934)
Career Advice (1999)
Deals (35384)
Drug Delivery (89)
Drug Development (80873)
Employer Resources (168)
FDA (16109)
Job Trends (14814)
News (344703)
Policy (32452)
Tag
Academia (2530)
Alliances (49244)
Alzheimer's disease (1283)
Approvals (16070)
Artificial intelligence (159)
Bankruptcy (354)
Best Places to Work (11596)
Biotechnology (199)
Breast cancer (201)
Cancer (1483)
Cardiovascular disease (119)
Career advice (1665)
Cell therapy (306)
Clinical research (64889)
Collaboration (547)
Compensation (302)
COVID-19 (2546)
C-suite (128)
Data (1451)
Diabetes (185)
Diagnostics (6188)
Earnings (85006)
Employer resources (146)
Events (110314)
Executive appointments (459)
FDA (16860)
Funding (497)
Gene therapy (212)
GLP-1 (614)
Government (4335)
Healthcare (18735)
Infectious disease (2642)
Inflammatory bowel disease (112)
Interviews (309)
IPO (16376)
Job creations (3625)
Job search strategy (1418)
Layoffs (424)
Legal (7866)
Lung cancer (220)
Manufacturing (213)
Medical device (13226)
Medtech (13231)
Mergers & acquisitions (19244)
Metabolic disorders (486)
Neuroscience (1634)
NextGen: Class of 2025 (6505)
Non-profit (4471)
Northern California (1845)
Obesity (277)
Opinion (185)
Parkinson's disease (105)
Patents (130)
People (56595)
Phase I (20194)
Phase II (28578)
Phase III (21292)
Pipeline (602)
Postmarket research (2561)
Preclinical (8551)
Radiopharmaceuticals (238)
Rare diseases (279)
Real estate (5893)
Regulatory (21758)
Research institute (2312)
Resumes & cover letters (349)
Southern California (1588)
Startups (3565)
United States (16345)
Vaccines (571)
Weight loss (191)
Date
Today (155)
Last 7 days (883)
Last 30 days (2121)
Last 365 days (35039)
2025 (1322)
2024 (35251)
2023 (40077)
2022 (51173)
2021 (55710)
2020 (54086)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (202)
Asia (37364)
Australia (6099)
California (4167)
Canada (1529)
China (352)
Colorado (188)
Connecticut (199)
Europe (80019)
Florida (586)
Georgia (141)
Illinois (409)
Indiana (237)
Maryland (673)
Massachusetts (3227)
Michigan (180)
Minnesota (312)
New Jersey (1168)
New York (1185)
North Carolina (777)
Northern California (1845)
Ohio (150)
Pennsylvania (984)
South America (1093)
Southern California (1588)
Texas (599)
Utah (118)
Washington State (425)
689,466 Results for "flugen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows Superiority Over Flu Shot Alone
July 12, 2024
·
5 min read
BioMidwest
New Data Published in the Journal of Infectious Diseases Demonstrate FluGen’s M2SR Vaccine Candidate Substantially Enhances Mucosal & Serum Antibodies Against Drifted Influenza Strains
FluGen, Inc. today announced the publication of new data in the Journal of Infectious Diseases showing its investigational, high dose, intranasal H3N2 M2SR influenza vaccine candidate substantially enhanced mucosal and serum antibodies against drifted H3N2 influenza viruses.
November 9, 2022
·
4 min read
BioMidwest
FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years
FluGen, Inc., today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s investigational supra-seasonal intranasal influenza (flu) vaccine, in volunteers ages 6 months to 17 years old.
September 7, 2022
·
4 min read
BioMidwest
FluGen to Present at the 40th Annual J.P. Morgan Healthcare Conference
FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced Boyd Clarke, Executive Chairman is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference.
January 5, 2022
·
1 min read
BioMidwest
FluGen to Present at Baird’s 2021 Global Healthcare Conference
FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced management is scheduled to present at the Baird 2021 Global Healthcare Conference on Tuesday, September 14 at 5:30 PM E.T.
September 7, 2021
·
1 min read
Press Releases
DiFusion Inc., Announces New Patent
January 14, 2025
·
1 min read
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Press Releases
Hologic Completes Acquisition of Gynesonics, Inc.
January 7, 2025
·
4 min read
Press Releases
GSK Enters Agreement to Acquire IDRx, Inc.
January 13, 2025
·
8 min read
Press Releases
LPOXY Therapeutics, Inc. Acquires Key Assets from Xeno Biosciences Inc. to Advance C. difficile Prevention Therapy
January 6, 2025
·
3 min read
1 of 68,947
Next
